Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.76 |
| ▸ | FSHR | P23945 | 16/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322278 | 0.88 | TSHR (0.82) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322918 | 0.84 | FSHR (0.71) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322357 | 0.83 | FSHR (0.71) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1323743 | 0.82 | MAPT (0.76) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322362 | 0.82 | FSHR (0.76) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1323374 | 0.81 | FSHR (0.71) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL6567374 | 0.81 | FSHR (0.74) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322285 | 0.81 | FSHR (1.00) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1322152 | 0.81 | FSHR (1.00) | TSHRFSHRMEN1ADRB2KMT2A | |
| SCHEMBL1323666 | 0.80 | FSHR (0.88) | TSHRFSHRMEN1ADRB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258293-B2 | Tetrahydroquinoline derivatives | MSD OSS B.V. (NL) | 2012-09-04 | — | — | US | disclosed |
| US-20120202996-A1 | TETRAHYDROQUINOLINE DERIVATIVES | N.V. ORGANON (NL) | 2012-08-09 | — | — | US | disclosed |
| US-8058441-B2 | For control fertility, contraception, breast cancer, prostate cancer and endometriosis; modulating activity of the follicle stimulating hormone (FSH) receptor; 1-Acetyl-6-(tert-butoxycarbonyl)amino-4-phenyl-1,2,3,4-tetrahydro-2,2,4-trimethylquinoline | N.V. ORGANON (NL) | 2011-11-15 | — | — | US | disclosed |
| EP-1406628-B1 | TETRAHYDROQUINOLINE DERIVATIVES | AKZO NOBEL NV (NL) | 2006-03-08 | — | — | EP | disclosed |
| US-20040236109-A1 | Tetrahydroquinoline derivatives | MERCK SHARP & DOHME B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
| EP-1406628-A1 | TETRAHYDROQUINOLINE DERIVATIVES | Akzo Nobel N.V. (NL) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004028-A1 | TETRAHYDROQUINOLINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202996-A1 | TETRAHYDROQUINOLINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ODC1, COX6C | TSHR 412/4885FSHR 1154/4885MEN1 2716/4885 |
| US-20040236109-A1 | Tetrahydroquinoline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AOC2, HTR3C | TSHR 725/4885FSHR 1485/4885MEN1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.